

www.nature.com/onc

CORRIGENDUM

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

MM Morrison, MM Williams, DB Vaught, D Hicks, J Lim, C McKernan, L Aurisicchio, G Ciliberto, C Simion, C Sweeney and RS Cook

Oncogene (2016) 35, 1206; doi:10.1038/onc.2015.418

Correction to: Oncogene (2016) 35, 1143-1152; doi:10.1038/onc. 2015.169; published online 6 July 2015

Since the online publication of this article the authors noticed an error in one of the authors' names. 'G Ciliberto' was erroneously given as 'G Cennaro'.

Furthermore, the authors would like to rectify the affiliations of two authors.

The affiliation for G Ciliberto should be as follows:

IRCCS National Cancer Institute 'G Pascale', via Mariano Semmola, 83131 Naples, Italy

The affiliation for L Aurisicchio should be:

Takis Biotech, via di Castel Romano 100, 00128 Rome, Italy

The authors apologise for any inconvenience caused by these errors.

These errors have now been rectified, and the corrected article appears in this issue. The html and online pdf versions have also been rectified, and now carry the corrected paper.